Report Abuse Reply to Author Print Note The author does not own any Elan stock at the present time but intends to purchase some on 2, 2005. The Nanocrystal technology takes advantage of the unique properties of nanoparticles to help improve the bioavailability of drugs. This is an important characteristic because large number of drugs produced by Big Pharma either fail or are abandoned due to poor watersolubility.

Individual Message Earlier this year, Roche began testing the Nanocrystal technology and it is already being used by Johnson & Johnson in Phase III clinical trial on injectible treatment for patients with Schizophrenia. I am also bullish on the stock because believe Elan management, the FDA and the broader investment community overreacted to the news about Tysabri. Note The author does not own any Elan stock at the present time but intends to purchase some on 2, 2005.

Reply to Author At the present timeand for the near futurethese products will make up only small portion of Elans overall business. posted by Jack Uldrich at PM 02, ReplyThe drop represent real opportunity for investors who have longterm perspective and understand the companys Nanocrystal technology. Earlier this year, Roche began testing the Nanocrystal technology and it is already being used by Johnson & Johnson in Phase III clinical trial on injectible treatment for patients with Schizophrenia.

Note The author does not own any Elan stock at the present time but intends to purchase some on 2, 2005. The Nanocrystal technology takes advantage of the unique properties of nanoparticles to help improve the bioavailability of drugs. At the present timeand for the near futurethese products will make up only small portion of Elans overall business. Earlier this year, Roche began testing the Nanocrystal technology and it is already being used by Johnson & Johnson in Phase III clinical trial on injectible treatment for patients with Schizophrenia.

From Bernie view profile Date Thurs, 1226am Email Bernie Rating 3 users show options Reply am also bullish on the stock because believe Elan management, the FDA and the broader investment community overreacted to the news about Tysabri. My bet is that Tysabri will be rereleased toward the end of this year and while it wont command as much of the market for MS treatments as was expected when it was first approved, it will still capture sizeable share.. This is an important characteristic because large number of drugs produced by Big Pharma either fail or are abandoned due to poor watersolubility.

Related Blogs